Recording of the effects of select AYUSH drugs, Ayush-64 and Kabasura Kudineer in Covid-19 patients in home isolation.

Phase 4

Conditions: Health Condition 1: B338- Other specified viral diseases

Registration Number: CTRI/2021/05/033623

Lead Sponsor: Ministry of AYUSH Govt of India

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

•Individuals of any gender within the age group 18-60 years

•Individuals diagnosed as COVID 19 and categorized as asymptomatic, mild or moderate disease

•within < One week of confirmation of COVID 19 disease

•Patients in home isolation under standard care as per the government guidelines

•Patients providing informed consent and willing to participate in the clinical study

Exclusion Criteria

•Patients not willing to use the Ayush interventions(AYUSH-64 &KabasuraKudineer)

•Pregnant, lactating women and other vulnerable population

•Use of immunosuppressive doses of corticosteroids prior to the enrollment in the study and planned use of immunosuppressive doses of corticoids

•Any other condition that, in the opinion of the principal investigator or his/her representative physician, could put the safety of potential participants at risk or prevent them from complying with this protocol.

•Patients who were diagnosed as having severe disease or receiving oxygen support.

•People who are unable to take oral medication

•People whose SpO2 levels are fluctuating within the range of 90-94.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
â?¢Demographic profiling of COVID 19 patients in home isolation, who received Ayush interventions(AYUSH 64 / Kabasurakudineer) as adjunct to standard care for asymptomatic, mild, and moderate COVID 19 in terms of geographic location, age, gender, education status, and domicile, based on the data reported through the Ayush Sanjivani appTimepoint: Day 1, Day 20

Secondary Outcome Measures